Emetic, central nervous system and pulmonary activities of rolipram in the dog

European Journal of Pharmacology

Volumn 286, Issue 3, 1995, Pages 281-290

  Heaslip, Richard J ^a   Evans, Deborah Y ^a  

^a WYETH AYERST RESEARCH   (United States)

Author keywords

Asthma; Bronchodilation; Cardiovascular; Central nervous system, dog; Emesis; Phosphodiesterase; Rolipram

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; INDOMETACIN; NADOLOL; ONDANSETRON; PENTOBARBITAL; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; SEROTONIN;

ANESTHESIA; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; BEHAVIOR; BREATHING RATE; BRONCHODILATATION; CARDIOVASCULAR RESPONSE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DOG; DRUG ANTAGONISM; FEMALE; HEART MUSCLE CONTRACTILITY; HEART RATE; INTRAGASTRIC DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REFLEX; SLEEP TIME; VOMITING;

ANIMAL; ANXIETY; ASTHMA; BRAIN; BRONCHI; DOGS; FEMALE; HEART RATE; MALE; NADOLOL; PENTOBARBITAL; PHOSPHODIESTERASE INHIBITORS; PYRROLIDINONES; RESPIRATION; ROLIPRAM; VOMITING;

EID: 0028882027     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-2999(95)00457-2     Document Type: Article

References (43)

1. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors
2. Multiple cyclic nucleotide phosphodiesterases
3. Rolipram versus imipramine in inpatients with major, ‘minor’ or atypical depressive disorder: a double-blind double-dummy study aimed at testing a novel therapeutic approach
4. Physiology and pharmacology of vomiting
5. Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides
6. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition
7. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol
8. Influence of rolipram on the cyclic 3′:5′-adenosine monophosphate response to histamine and adenosine in slices of guinea pig cerebral cortex
9. Effects of phosphodiesterase inhibition on the excitability of hippocampal pyramidal neurons in vitro
10. Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma?
11. Behavioral effects of rolipram and structurally related compounds in mice: behavioral sedation of cAMP phosphodiesterase inhibitors
12. Central mechanisms for apomorphine-induced emesis in the dog
13. m cAMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig
14. Bronchodilatory activity and selectivity of WAY-PDA-641 rolipram and aminophylline in the anesthetized rat
15. Bronchial vs. cardiovascular activities of selective phosphodiesterase inhibitors in the anesthetized beta-blocked dog
16. Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641
17. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine
18. Cardiovascular effect and stimulus-dependent inhibition of superoxide generation from human neutrophils by tibenelast, 5,6-diethoxybenzo(b)thiophene-2-carboxylic acid, sodium salt (LY186655)
19. Neurotransmitters in anxiety
20. Comparative effects of caffeine and selective phosphodiesterase inhibitors on respiration and behavior in rhesus monkeys
21. Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs
22. Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram
23. Effects of novel catechol ether imidazolidinones on calcium-independent phosphodiesterase activity, [3H]-rolipram binding, and reserpine-induced hypothermia in mice
24. Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences
25. Clinical and biochemical effects of the selective phosphodiesterase inhibitor rolipram in depressed inpatients controlled by determination of plasma level
26. Aminophylline shortens thiopental sleep-time and enhances noradrenergic neurotransmission in rats
27. Anaesthesia; the role of adrenergic mechanisms
28. Brain noradrenaline and anaesthesia; further characterization of the beta receptor
29. Brain noradrenaline and anaesthesia; behavior and electrophysiological evidence
30. Differential regulation of TNF-α and IL-1β production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors
31. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes - their potential utility in the therapy of asthma
32. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes
33. Efficacy of denbufylline in patients with multi-infarct dementia
34. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3′:5′-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain
35. Effect of isozyme-selective inhibitors of phosphodiesterase on histamine-stimulated cyclic AMP accumulation in guinea pig hippocampus
36. Effect of phosphodiesterase inhibitors on cell influx in ovalbumin sensitized guinea pigs
37. Action of mediators on airway smooth muscle Functional antagonism as a mechanism for bronchodilator drugs
38. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma
39. Effects of rolipram on responses to acute and chronic antigen exposure in monkeys
40. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram
41. Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3′:5′-monophosphate phosphodiesterase inhibitors
42. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′:5′-monophosphate phosphodiesterase inhibitors
43. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility